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Human skin fatty acids are a potent aspect of our innate defenses, giving surface protection against potentially invasive organ-
isms. They provide an important parameter in determining the ecology of the skin microflora, and alterations can lead to in-
creased colonization by pathogens such as Staphylococcus aureus. Harnessing skin fatty acids may also give a new avenue of ex-
ploration in the generation of control measures against drug-resistant organisms. Despite their importance, the mechanism(s)
whereby skin fatty acids kill bacteria has remained largely elusive. Here, we describe an analysis of the bactericidal effects of the
major human skin fatty acid cis-6-hexadecenoic acid (C6H) on the human commensal and pathogen S. aureus. Several C6H con-
centration-dependent mechanisms were found. At high concentrations, C6H swiftly kills cells associated with a general loss of
membrane integrity. However, C6H still kills at lower concentrations, acting through disruption of the protonmotive force, an
increase in membrane fluidity, and its effects on electron transfer. The design of analogues with altered bactericidal effects has
begun to determine the structural constraints on activity and paves the way for the rational design of new antistaphylococcal
agents.
The human skin provides important protection against micro-bial infection. The epidermis provides a physical barrier via an
external cross-linked keratin layer upon a scaffold of keratino-
cytes. Most importantly, the skin also has a broad range of innate
immunity components, including antimicrobial peptides and
fatty acids (1, 2, 3). Despite these properties, the skin is host to a
large and complexmicroflora of1,000 species (4).Many of these
microorganisms are harmless commensals, but there are also op-
portunist pathogens. Thus, how the skin is able to defend against
potentially dangerous organisms is of great interest, as harnessing
our innate defenses may lead to novel control regimens.
Staphylococcus aureus is an extremely versatile bacterium,
whose primary niche is as a commensal in the human nose. De-
spite being carried harmlessly by 30% of the human population,
this organism is an opportunist pathogen causingmany infections
and deaths worldwide (5). The problem is exacerbated by the
alarming spread of antibiotic resistance; in particular, methicillin-
resistant S. aureus (MRSA) is prevalent in hospitals and is begin-
ning to spread in the wider community. The ability of S. aureus to
survive in the nares and on the skin is an important facet of its
capacity to spread from host to host. In particular, skin fatty acids
in sebum have been found to be potent staphylocidal agents (3, 6,
7). Fatty acids are an important facet of our innate defenses, and in
fact, a Toll-like receptor-mediated pathway in mice leads to in-
creased fatty acid production and protection against S. aureus skin
infections (8). The most important antistaphylococcal human
skin fatty acid is cis-6-hexadecanoic acid (C6H) (3, 7). Patients
with atopic dermatitis show reduced C6H levels and increased
colonizationwith S. aureus, and in these patients topical treatment
with C6H results in a decrease in S. aureus levels (7). We have also
shown that purified C6H treats both cutaneous and systemic
models of S. aureus disease (9). Fatty acids also kill S. aureuswithin
abscesses (10). As well as being bactericidal, human sebum and
C6H at sublethal concentrations inhibit the production of viru-
lence determinants and the induction of antibiotic resistance by S.
aureus and other important pathogens (9). Thus, fatty acids can
debilitate potentially harmful bacteria at several levels.
In response to such a potent molecule, S. aureus possesses a
number of resistance mechanisms, which allow it to withstand
skin fatty acids (9, 11). We have found that the major S. aureus
surface protein, IsdA, is produced in response to the lack of avail-
able iron associated with the human host and is required for nasal
colonization (9). IsdA contributes to skin fatty acid resistance by
rendering the cells more hydrophilic via its C-terminal domain. It
is also this domain that is required for survival of S. aureus on
human skin. Thus, the interaction between S. aureus and human
skin fatty acids is a crucial factor in its ability to colonize a host.
Despite the importance of this ability, the bactericidal mechanism
of action of skin fatty acids on S. aureus is still unknown. The
surfactant nature of these compounds likely results in membrane
perturbation. Fatty acids also inhibit many central metabolic pro-
cesses, but this may occur indirectly via uncoupling of ATP syn-
thesis (12, 13). In addition, the accumulation and incorporation
of linoleic acid (12, 14) may result in toxic lipid hydroperoxides
(15, 16). In this study, we aimed to elucidate themode of action of
the major staphylocidal skin fatty acid, C6H, on S. aureus. This
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revealed multiple mechanisms of killing via the ability of C6H to
disrupt essential membrane functions.
MATERIALS AND METHODS
Bacterial strains and chemicals. S. aureus strain SH1000 was used in all
assays except as otherwise stated. Inverted vesicles and membranes were
prepared from Micrococcus flavus and Escherichia coli K-12. All chemicals
were purchased from Sigma-Aldrich except as otherwise stated. Radiola-
beled [14C]UDP N-acetylglucosamine (UDP-GlcNAc) was from Hart-
mann Analytic (Germany) and undecaprenyl phosphate (C55-P) was
fromLarodan FineChemicals (Sweden). Bacteria were routinely grown in
brain heart infusion (BHI) medium aerobically; for anaerobic growth,
cells were grown in airtight anaerobic jars.
C6H killing assays. Bacteria were grown to an optical density at 600
nm (OD600) of0.6 in iron-limited tryptic soy broth (TSB) or chemically
defined medium (CDM) (17). Cells were harvested by centrifugation at
3,000  g (at 4°C for 5 min) and washed twice in sterile distilled water
(dH2O) by centrifugation and resuspension. Cell suspensions (2 10
8
CFU/ml in appropriate buffers) were incubated at 37°C with and without
C6H (and other chemicals). Except when stated otherwise, all experi-
ments were done in 20 mM morpholineethanesulfonic acid (MES) (pH
5.5) with 3 g/ml C6H. Cell viability was determined by plating on TSB
agar (9).
MICs. MICs were determined as previously described (9).
Assessment of membrane integrity.Membrane integrity was assayed
by determination of the permeability of the cells to propidium iodide (PI).
Nisin served as a positive control for membrane disruption. Bacteria were
prepared as for the C6H killing assay (in 20 mM MES) and PI was added
to the cell suspension to a final concentration of 13 M. Fluorescence of
the mixture was followed with excitation at 535 nm and emission at 617
nm (18). After a 1-min equilibration time, C6Hwas added to the assay (at
3 or 5 g/ml).
Effect of C6H on lipid II polymerization. Lipid II was purified as
described by Schneider et al. (19). The enzymatic activity of S. aureus
penicillin-binding protein 2 (PBP2) was determined by incubating 2.5
nmol lipid II in 100 mMMES, 10 mMMgCl2 (pH 5.5), and 0, 2, 4, 20, and
40 nM C6H in a total volume of 50 l. The reaction was initiated by the
addition of 7.5g PBP2-His6 and incubated for 1.5 h at 30°C. Residual lipid
II was extracted from the reaction mixtures with n-butanol-pyridine acetate
(pH 4.2) (1:1, vol/vol), and analyzed by thin-layer chromatography (TLC)
(silica plates [60F254];Merck) using chloroform-methanol-water-ammonia
(88:48:10:1, vol/vol) as the solvent (20). Spots were visualized by phorbol
myristate acetate (PMA) staining reagent (phosphomolybdic acid 2.5% [vol/
vol], ceric-sulfate 1% [wt/vol], and sulfuric acid 6% [vol/vol]). After the TLC
plate was dried, spots were developed by heating at 150°C (21).
Inhibition of in vitro lipid II synthesis. Inhibition of lipid II synthesis
was performed in vitro using membrane preparations of Micrococcus lu-
teus DSM 1790 as described by Schneider et al. (19) with the addition of
radiolabeled [14C]UDP-GlcNAc. Membranes were isolated from ly-
sozyme-treated cells by centrifugation (40,000  g for 60 min at 4°C),
washed twice in 50mMTris-HCl and 10mMMgCl2 (pH 7.5), and stored
under liquid nitrogen until use. Reaction mixtures were carried out in a
final volume of 75l and contained 400g of membrane protein, 5 nmol
undecaprenyl phosphate (C55-P), 50 nmol UDP-N-acetylmuramyl pen-
tapeptide (UDP-MurNAc-PP), 50 nmol [14C]UDP-GlcNAc in 60 mM
Tris-HCl (pH 8), 5 mM MgCl2, and 0.5% (wt/vol) Triton X-100. UDP-
MurNAc-PP was purified as described previously (22). C6Hwas added to
the reactionmixture inmolar ratios of 2:1 (referring to the total amount of
C55-P [5 nmol]). After 1 h at 30°C, the lipidswere extractedwith 1 volume
of n-butanol-6 M pyridine-acetate (2:1, vol/vol) (pH 4.2). The reaction
products were separated by TLC (silica plates [60F254]; Merck) using
chloroform-methanol-water-ammonia (88:48:10:1) as the solvent (20).
Radiolabeled spots were visualized using a biomolecular imager for radio-
isotope detection (Storm 820 PhosphorImager; Amersham Biosciences)
and the image was analyzed with ImageQuant TL v 2005 (Nonlinear Dy-
namics, Ltd.) software.
Determination of membrane potential using tetraphenylphospho-
nium ion (TPP). To 5 ml of cell suspension (prepared as described
above) at 37°C, 5 l of [3H]tetraphenylphosphonium ([3H]TPP) (final
concentration, 1Ci/ml [0.74 to 1.48 TBq/mmol]) was added. One-hun-
dred-microliter samples were removed, washed with phosphate-buffered
saline (PBS) by filtration, and used to calculate total emission. Where
appropriate, valinomycin and/or C6H was added (20 and 3 g/ml final
concentrations, respectively), and samples were prepared as described
above. Calculation of the membrane potential () was performed as
previously described (23).
Assessment of intracellular pH. The experiments and controls were
performed as previously described by Breeuwer et al. (24) using cells pre-
pared as described above.
ATP assays.Cell suspensionswere prepared as described above. Samples
(200l) were taken and 800l dimethyl sulfoxide (DMSO)was added. Cells
were recovered by centrifugation (10,000 g for 5min at room temperature
[RT]), and the supernatant was removed for analysis of extracellular ATP.
ATP levels were measured using a bioluminescence assay (Sigma).
Respiration. Cells grown as above for the killing assays were resus-
pended to an OD600 of 1.0 in iron-limited TSB and transferred to a
Clark-type oxygen electrode chamber, and oxygen consumption was re-
corded.
Membrane fluidity. Cell membrane fluidity was determined by mea-
suring fluorescence polarization with 1,6-diphenyl-1,3,5-hexatriene
(DPH) (Sigma), as described by Bayer et al. (25). A 1-ml S. aureus cell
suspension was prepared as described above (OD600 of1.0) andDPH (2
M final concentration) was added. Fluorescence polarization was mea-
sured immediately after addition of inhibitor to the labeled sample (1 ml)
using an Edinburgh Instruments 199 spectrometer. The excitation and
emission wavelengths were 360 and 426 nm, respectively. The degree of
fluorescence polarization, or the polarization index, was calculated with
the formula [IV  IH (IHV/IHH)]/[IV 	 IH (IHV/IHH)], where I is the
corrected fluorescence intensity and the subscripts V and H indicate the
values obtained with vertical or horizontal orientation of the analyzer,
respectively. The lower the polarization index value, the more fluid the
membrane (25, 26, 27).
Iodonitrotetrazolium chloride reduction assay.Reduction of the io-
donitrotetrazolium chloride (INT) by the components of the electron
transport chain (ETC)was performed as described by Smith andMcFeters
(28) in a 250-l volume reaction.
Preparation of inverted vesicles. Inverted vesicles were prepared us-
ing a method adapted from Burstein et al. (29). Cells from a 1-liter TSB
post-exponential-phase culture (OD600, 3 to 4) were harvested by centrif-
ugation (3,000  g for 10 min at 4°C) and washed with 100 ml buffer
containing 50 mM Tris-HCl (pH 8.0), 2 mMMgCl2, 0.5 mM dithiothre-
itol, and 0.5mMEDTA. The pellet was resuspended with 5ml of the same
buffer, the pH was adjusted to 8.0, and 10 g/ml DNase and 10 g/ml
RNase were added. The cells were disrupted by mechanical lysis using a
microorganism lysing kit (0.1-mm glass beads in 2-ml standard tubes) in
a Precellys 24 homogenizer. The crude homogenate was centrifuged at
30,000 g (for 20min at 4°C). The resulting supernatant was centrifuged
at 175,000 g (for 120 min at 4°C) and the pellet containing the vesicles
was finally resuspended in 2 ml of the above buffer supplemented with
10% (vol/vol) glycerol and stored in liquid nitrogen.
Liposomes. Liposomes were prepared and quantified according to
Bonelli et al. (30). We dried 2 mol 1,2-dioleoyl-sn-glycero-3-phospho-
choline (DOPC) (Avanti Polar Lipids) in a glass tube and then added 300
l of a solution of 50-mM carboxyfluorescein and 50mMNaCl or KCl to
the dried DOPC. The glass tube was vortexed thoroughly, freeze-thawed
10 times, and then extruded through a 400-nm pore membrane. Lipo-
somes were loaded on a Sephadex G50 column preequilibrated with the
appropriate buffer and harvested by centrifugation (13,000 g for 1 min
at RT).
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Production of C6H analogues. The synthesis of C6H analogues and
Bodipy dyes were carried out by sequential alkylation of alkynyl anions
with appropriate alkyl and tetrahydropyranyl alkyl bromides, followed by
dichromate oxidation to the carboxylic acid. Comprehensive details will
be reported in due course. A method describing a similar strategy to pro-
duce related compounds has recently been described in the literature (31).
Transmission electron microscopy. Samples were prepared and an-
alyzed as previously described (32).
Fluorescence microscopy. We added 17 M Bodipy 1 (in DMSO)
and 10 l of a 1-g/ml solution of Bodipy-labeled vancomycin (vanco-
mycin, Bodipy FL conjugate; Invitrogen) to 1 ml of S. aureus (grown as
above) and incubated the mixture for 5 min at 37°C on a rotary wheel (20
rpm). The cells were harvested by centrifugation (10,000 g for 1 min at
4°C), washed 3 times by resuspension in dH2O, fixed, mounted, and ex-
amined by deconvolution microscopy as previously described (33).
Ion level determination. Cells were grown and treated as for the kill-
ing assays described earlier. At each time point, required cells were har-
vested by centrifugation (10,000  g for 1 min at 4°C) and ion levels
within the supernatant were monitored via the ion chromatography ser-
vice (Kroto Centre, University of Sheffield).
Statistics. Student’s t test was used where appropriate.
RESULTS
Characterization of the bactericidal effects of C6H. Previous
work has demonstrated that C6H kills S. aureus (7, 9). It is well
established that the pH of the skin is slightly acidic (34) and so the
effect of pH on C6H sensitivity was tested (Fig. 1A). S. aureus
shows greatest survival at pH 5.5 (skin pH) without C6H, losing
only 50% viability after 2 h. Paradoxically, 5 g/ml C6H has its
greatest activity at pH 5.5, with only 0.5% survival after a 2-h
treatment in MES buffer (Fig. 1B). There is also a clear C6H dose
dependence in S. aureus survival at pH 5.5 (Fig. 1C). At 10g/ml,
C6H viability is quickly lost (99% death after 30 min). At 3 and
5 g/ml C6H, 60 and 99% of cells were nonviable after 30 min,
respectively.
In order to begin to determine the molecular mechanism of
C6H bactericidal activity, propidium iodide (PI) was used. PI
fluorescence greatly increases upon binding to nucleic acids
and so it can be used as a marker for membrane integrity when
added to the extracellular milieu. At pH 5.5, only concentra-
tions of C6H above 3 g/ml led to a rapid loss of membrane
integrity, as shown by an increase in fluorescence (Fig. 2A and
B). However, at 3 g/ml C6H the cells still died. This suggests
that death can occur independently of drastic membrane per-
meabilization.
Inhibition of C6H activity by salts. Potassium ions have pre-
viously been shown to affect fatty acid activity on mitochondria
(35). Addition of 50 mM KCl to 50 mM MES (pH 5.5) gave a
significant reduction in the rate of killing by 5 g/ml C6H (P 

0.03 at 60 min) but to a lesser extent by 3g/ml C6H (P
 0.19 at
60 min) (Fig. 1C). Addition of NaCl or CaCl2 had a similar inhib-
itory effect (data not shown). Salt inhibition of C6H activity fur-
ther suggests more than one mode of killing, disruption of mem-
brane integrity and an uncharacterized mechanism at lower
concentrations (3g/ml). The binding of PI to nucleic acid was
FIG 1 Characterization of the bactericidal effect of C6H. Effect of external pH on bactericidal activity. S. aureus cells were incubated (for 2 h at 37°C) in various
buffers (20 mM N-cyclohexyl-3-aminopropanesulfonic acid [CAPS; pH 10], 25 mMHEPES [pH 7.4], 20 mM PBS [pH 7.4], 20 mM sodium citrate buffer [pH
5.5], and 20mMMES [pH 5.5]). (A) Percentage of surviving cells with no C6H compared to the percentage of cells at 0min. (B) Percent survival of the cells after
incubation with 5 g/ml C6H compared to percent survival of the cells with no C6H at the same time point. (C) Survival kinetics and the effect of KCl on C6H
activity. The effect of 3 and 5 g/ml C6H ( and, respectively) with (open symbols) or without (filled symbols) 50 mMKCl (, 10 g/ml C6H). For all data
points, the percent survival was compared to that of the wild type at the same time.
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inhibited in the presence of salt, hence preventing the fluorescence
assay.
DoesC6Haffect peptidoglycan synthesis?Previously, the lan-
tibiotic nisin has been shown at low concentrations to associate
with lipid II (a precursor in the peptidoglycan biosynthesis path-
way), which leads to simultaneous inhibition of cell wall biosyn-
thesis and formation of defined pores in the cell membrane. At
high concentrations it has several other effects, such as induction
of autolysis and destabilization of the lipid bilayer (36). Initially,
usingM. luteus isolatedmembranes, C6Hwas foundnot to inhibit
the synthesis of lipid II (data not shown). The effect of C6H on
peptidoglycan synthesis via binding to lipid II was then tested.
Using nisin as a positive control, we found that C6H had no ap-
parent capacity to bind lipid II or to inhibit the activity of S. aureus
PBP2, which polymerizes lipid II (data not shown).
C6H affects the proton motive force. Fig. 1B demonstrates
that S. aureus is more susceptible to C6H at low pH. At pH 5.5,
C6H of 3g/ml leads to cell death (Fig. 1C), but without apparent
loss of membrane integrity (Fig. 2A). The action of C6H may
involve movement of protons across the membrane, with C6H
acting as a protonophore. The protonmotive force (PMF) has two
components, membrane potential () and proton gradient
(pH) (PMF,p
 59pH). The cells use both to generate
ATP, using the flow of protons through the ATPase. A protono-
phore affects both components of the PMF. At high concentra-
tions of C6H (5 g/ml), the membrane depolarizes rapidly to
become unpolarized (data not shown). Lower concentrations of
C6H (3g/ml) led to an apparent membrane depolarization (Fig.
2C) and then slower repolarization thanwith valinomycin.Hence,
C6H affects the  component of the PMF.
ThepHwas measured using the fluorophore cFDASE. Intra-
cellularly, the ratio of the emissions at 530 nm for excitation levels
at 500 and 440 nm is a marker of pH. By calibrating that ratio it is
then possible to assess the intracellular pH. High concentrations
of C6H (5 g/ml) led to a rapid drop of internal pH within
minutes, resulting in an equilibration of the internal pH with the
outside pH of 5.5 (data not shown).With 3g/ml C6H, the inter-
nal pH drops rapidly by around 0.1 pH unit in 2 min and then
stabilizes (Fig. 3). It appears that at 3 g/ml C6H, protons are
being carried into the cell even though themembrane is still intact.
Thus, C6H has protonophore activity and at high concentrations
can act as a likely surfactant.
C6H reduces internal ATP levels. Two minutes after the ad-
dition of a high concentration of C6H (5 g/ml), the ATP level
inside the cell drops by 85%, while the percentage of ATP outside
cells increases by40% (data not shown). This is consistent with
the damage to the membrane, which allows ATP to be released.
With 3g/ml C6H the cells lose around 93%ATPwithin 2min of
incubation (Table 1), while the ATP outside the cell increases only
FIG 2 Effect of C6H on membrane integrity (A and B) and potential (C). (A)
Cells were incubated with PI for 1min and 20mMMES before addition (black
arrow) of 3g/ml C6H (black curve) and 5g/ml C6H (gray curve). (B) Effect
of C6H on the rate of PI fluorescence increase. (C) Membrane potential was
measured for 10 min before (at 0 min) the addition of 3 g/ml C6H (), 20
g/ml valinomycin (Œ), 3g/ml C6H, or 20g/ml valinomycin () and after
no addition ().
FIG 3 C6H reduces the ability to control internal pH in S. aureus. Effect of
C6H on fluorescence ratio of cFDASE (left ordinate) and corresponding pH
(right ordinate). C6H (3 g/ml) was added (filled arrow), followed by excess
amounts of nigericin and valinomycin (white arrow).
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by 10% compared to the untreated sample (data not shown).
The drop in ATP levels may be due to the use of energy by the cell
to restore the andpH and/or cessation of ATP synthesis due
to loss of the proton gradient required for its production.
Effect of C6H in combination with other inhibitors. In order
to further elucidate the potential mechanism of C6H activity, its
effects were determined in combination with inhibitors of known
function. The protonophore carbonyl cyanide m-chloro phenyl
hydrazone (CCCP) is a very powerful uncoupling agent that car-
ries protons across the membrane, resulting in loss of both pH
and  (37). C6H and CCCP have an additive effect on S. aureus
killing (Table 2), with an associated drop in ATP levels (Table 1).
Valinomycin is a potassium carrier which equilibrates intra-
and extracellular levels. It affects  and can either depolarize or
hyperpolarize the cells, depending on the extracellular K	 levels.
When valinomycin was used alone, this resulted in only a small
loss of ATP, and when used in combination it prevented the dras-
tic loss seenwithC6Halone (Table 1). Valinomycin leads tomem-
brane hyperpolarization, in contrast to C6H (Fig. 2C), and with
valinomycin and C6H in combination, the membrane becomes
transiently hyperpolarized for 5 min prior to a slow return to
control levels. With the combination of inhibitors there is also an
additive effect in terms of S. aureus killing (Table 2). Addition of
KCl significantly reduces the bactericidal effect of both C6H and
valinomycin (Table 2).
Dicyclohexylcarbodiimide (DCCD) is a direct inhibitor of
ATPase and affects the pH. DCCD caused significant death of S.
aureus (Table 2), but when DCCD was used in combination with
C6H there was no increase in killing. In addition, DCCD alone
resulted in only a small loss of ATP, and in combinationwith C6H
more ATPwasmaintained than with C6H alone (Table 1). DCCD
inhibits the activity of ATPase, thus preventing the use of ATP
while extruding protons. As DCCD-treated cells did not lose a
significant amount of ATP under the conditions usedwith 20mM
MES (pH 5.5) (Table 1) (P
 0.58), it appears that the cells are not
metabolically active under these conditions.
C6H inhibits the electron transport chain. The effect of C6H
on the electron transport chain (ETC) was studied using inverted
vesicles and iodonitrotetrazolium chloride (INT) (28). INT is re-
duced by almost all the components of the ETC, forming iodon-
itrotetrazolium violet formazan (INF), which can be colorimetri-
cally quantified. NADH or succinate substrate was added to
generate the electron flow. Inhibition of the ETC downstream of
the site of INT reduction, i.e., closer to the terminal oxidase (com-
plex IV), should either increase or not affect the amount of form-
azan compared to control (28). The effect of C6Hon the ETCwith
Escherichia coli inverted vesicles is shown in Fig. 4 and was con-
firmed withMicrococcus flavus inverted vesicles (data not shown).
Inhibition of the first components of the ETC, complex I by rote-
none in the NADH reaction and complex II by malonate when
succinate was used as the substrate, resulted in a decrease of INF
formed, whereas inhibition of complex IV by sodium azide re-
sulted in an increased amount of INF (Fig. 4). Similar to NaN3,
C6Hproduced larger amounts of formazan. However, no effect of
the C6H was seen in the absence of an electron flow, for instance
when used in combination with rotenone ormalonate.Moreover,
a cumulative effect in combination with NaN3 was observed, sug-
gesting that C6H interferes with the electron flow through the
ETC. Confirmation will require the establishment of the assays
using the native S. aureus system.
Effect ofC6Honexternal ion levels. Ion chromatography (IC)
was used to determine the effects of inhibitors (C6H and CCCP)
on ion levels. Of the extracellular ions tested, all were unchanged
(data not shown) in the presence of inhibitors (apart fromK	). As
expected, CCCP leads to K	 extrusion (6.49  0.02 and 2.67 
0.15 ppm for the CCCP treated and controls, respectively), which
most likely occurs during reestablishment of the membrane po-
tential. C6H also results in significant release of K	 (4.47  0.14
ppm; P 0.01 compared to the control).
Anaerobic growth leads to increased C6H resistance. To test
the hypothesis that C6H is a protonophore, the MIC for C6H in
chemically defined medium under aerobic and anaerobic condi-
tions was tested. Anaerobically grown S. aureus is not dependent
on the PMF for survival. Anaerobically grown cells have anMICof
60 g/ml, around 6-fold higher than aerobically grown cells (10
g/ml).
C6H inhibits respiration. The addition of half-MIC C6H (5
g/ml) to S. aureus in TSB iron limited led to a 6-fold reduction in
respiration rates (0.09 0.01 and 0.58 0.13 mol O2/ml · s for
C6H treated and control, respectively; P  0.0001), whereas 5
TABLE 1 Effects of inhibitors on intracellular ATP levelsa
C6H (g/ml)
ATP level (mean SD) (%) (P) after 2-min incubation with:
No inhibitor 20 g/ml DCCD 0.5 g/ml CCCP 10 g/ml valinomycin
0 96.4 10.9 84.7 12.9 (0.58) 17.8 6.3 (0.01) 78.9 28.9 (0.49)
3 6.7 0.3 68.8 11.9 (0.01) 3.2 0.3 (0.01) 46.2 3.2 (0.01)
a Cells were incubated for 2 min in 20 mM MES (pH 5.5) in the presence or absence of C6H and different inhibitors. ATP levels were determined (expressed as a percentage of the
level at 0 min). P values are shown for the comparison of inhibitor-treated samples to their respective controls (with or without C6H).
TABLE 2 Effect of C6H and inhibitors on survival of S. aureusa
Addition
Survival (mean SD) (%) at 90 min compared to untreated control for:
Control 50 mM KCl 20 g/ml DCCD 0.5 g/ml CCCP 10 g/ml valinomycin
10g/ml valinomycin,
50 mM KCl
None 100 91.5 10.6 12.9 3.5 32.2 6.6 2.1 0.1 35.8 5.1
3 g/ml C6H 7.4 1.8 26.5 6.7 10.1 3.2 1.1 0.5 0.06 0.05 8.6 0.8
a Cells were incubated in the presence or absence of C6H, inhibitors, and KCl for 90 min. All values are expressed as the percent survival compared to the untreated control at 90
min. KCl greatly enhanced survival in the presence of C6H, with or without valinomycin (P 0.01 compared to no-KCl control in both cases).
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g/ml CCCP (10 MIC) had no significant effect (0.56  0.07
mol O2/ml · s; P
 0.83).
C6Hincreasesmembranefluidity.1,6-Diphenyl-1,3,5-hexatriene
(DPH) is a hydrophobic fluorophore which intercalates between the
phospholipids of the bacterial membrane and orients perpendicu-
larly to themembraneplane.ThefluorescenceofDPHdependson its
environment and increases with hydrophobicity. It predominantly
reflects the structural order of membrane lipids, mainly as a result of
preferential partitioning of the probe into the hydrocarbon phase of
the lipid bilayer membranes. Thus, membrane fluidity may be con-
sidered the reciprocal of the structured order of membrane lipids.
The polarization index value reflectsmembrane fluidity. An increase
of thepolarization index equates to an increase inmembrane rigidity,
while a decrease of the polarization index correlates with increased
membrane fluidity.
Addition of C6H led to a decreased polarization index of the
bacteria as a result of increased membrane fluidity (Fig. 5). In
contrast, CCCP resulted in an increase in membrane rigidity (Fig.
5). This is possible evidence thatC6H localizes to themembrane of
S. aureus cells. Thus, although both C6H and CCCP are protono-
phores, they have different mechanisms of action.
Action of C6H in liposomes. Liposomes that held the fluoro-
phore carboxyfluorescein (for which the fluorescence is pH de-
pendent) were used to test the effect of Na	 and K	 ions on the
C6H effect. The liposome inclusion had a basic pH due to the
solubilization of the fluorophore in sodium hydroxide, which
gave a background stable fluorescence. Liposomes also included
either 50mMKCl or 50mMNaCl. Addition of 50g/mlC6H (the
concentration needed to see an effect in this artificialmodel) led to
a drop in fluorescence synonymous with a drop of pH inside the
liposomes (5.09 2.5 and 0.69 0.6 absorbance units [AU]/min,
respectively, for KCl- and NaCl-filled liposomes). Interestingly,
the rate of loss of fluorescence is greater with KCl in the liposomes
(P 
 0.01). This suggests that C6H carries protons into the lipo-
somes and then is flipped back with a K	 ion. This would allow
C6H to then transfer another proton and so increase the rate of
fluorescence drop by DPH.
Cell morphology. C6H increases membrane fluidity, reduces
ATP levels, and leads to cell death. Electronmicroscopy (EM) was
used to determine if C6H morphological changes occur. After a
2-h killing assay with or without 5 g/ml C6H, samples were pre-
pared for EM imaging. During this timemany cells had developed
multiple and aberrant positioning of the septa (Fig. 6), possibly as
a result of membrane damage. At 3 g/ml C6H, no significant
morphological changes were apparent (data not shown).
Antimicrobial activity of C6H analogues. In order to begin to
define the structure-function relationship for C6H, and the po-
tential for novel antimicrobials, a number of analogues were syn-
thesized. A number of alkynyl acids and alcohols were synthesized
and tested for activity (Fig. 7 and data not shown). All alkynyl/
alkenyl alcohols were biologically inactive against S. aureus; thus,
the polar nature of the carboxylic acid group is important in the
bactericidal activity of C6H. A degree of fatty acid unsaturation is
required, as palmitic acid, the completely saturated analogue of
C6H, showed minimal activity. Interestingly, the trans isomer of
C6H was not as biologically active against S. aureus as the cis iso-
mer. However, alkynyl (triple-bond) analogues of C6H also
showed killing similar to C6H levels, further reinforcing the hy-
pothesis that unsaturation of the acid is important for activity
(data not shown).
Interestingly, one of the synthetic analogues (C8) has a higher
efficacy against S. aureus than C6H (Fig. 7). This compound was
used to develop a fluorescent derivative for localization studies
(Bodipy 1). Bodipy 1 still retained some antibacterial activity com-
pared to an untreated control (Fig. 7). The reduction in the killing
ability of Bodipy 1 compared to alkynyl acid C8 is attributable to
the increase in size of the antimicrobial agent. Bodipy 1 was then
used to determine its localization during treatment of S. aureus,
using vancomycin as a control for cell wall localization (32). Van-
comycin (Fig. 8) shows the characteristic labeling with a focus at
the septum, where cell wall synthesis is occurring. Bodipy 1 is an
excellent fluorophore, with exceptional brightness at the concen-
tration used (Fig. 8). Bodipy 1 also partitions into the cell envelope
and does not accumulate in the cytoplasm (Fig. 8). Bodipy 1 does
not demonstrate the pronounced septal localization of vancomy-
cin and partitionsmore consistently throughout themembrane of
S. aureus (Fig. 8e).
FIG 5 C6H increases S. aureus membrane fluidity. Polarization index (PI)
dynamics were measured after treatment of S. aureus cells with C6H or CCCP
(0.5 g/ml).
FIG 4 Effect of C6H and various inhibitors on the electron transport chain of
E. coli inverted vesicles. NADH (left) and succinate (right) were used as the
substrates to generate the electron flow. Data are expressed as percent devia-
tions in formazan production from substrates alone using the INT reduction
assay.
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DISCUSSION
Human skin fatty acids are an important facet of innate immunity.
In particular, C6H has been found to be the most effective anti-
staphylococcal fatty acid on human skin (7). Altered fatty acid
metabolism and consequent reduction in C6H levels correlates
with cases of atopic dermatitis and increased colonization by S.
aureus (7). In fact, purified C6H is used to treat atopic dermatitis
and reduce S. aureus levels (7). Thus, if one is to develop C6H or
related molecules as potential prophylaxis or therapy, its mode of
action needs to be established. The bactericidal activity of fatty
acids requires them to be in the acid form (the ester form does not
kill), to have a length of14 carbons, and to be unsaturated (38,
39, 40, 41). C6H is a 16-carbon, monounsaturated fatty acid (42,
43) made by the sebaceous glands from the widely available satu-
rated palmitic acid (44). We have found that there are specific
functional group characteristics that are essential for the activities
of these molecules. Whether this effect is through a direct molec-
ular interaction of the unsaturation with a key target in the cell
membrane, or through changes induced in the shape of thesemol-
ecules at the macromolecular level, is not clear. Further studies
aimed at examining the key roles of the pharmacophores in these
fatty acids are currently being conducted.
Although several bactericidal mechanisms of fatty acid activity
have been postulated, they have remained elusive. We propose
that C6H kills S. aureus in several ways. It is also possible that
subpopulations of the cells may exhibit altered susceptibility to
C6H. All mechanisms are linked and require C6H to access and
partition into the bacterial membrane. In support of this, analysis
of the fluorescent analogue Bodipy 1 demonstrated cell envelope
localization for this compound. At low concentrations, dependent
on the physicochemical environment and the metabolic status of
the cells, C6H increases membrane fluidity and has a protono-
phore effect. C6H leads to a loss of membrane potential and an
inability to control internal pH. This explains why C6H is more
effective in killing S. aureus at the acidic pH of the skin (pH 5.5).
The acidic group on the fatty acid C6H is likely essential for its
proposed protonophore effect. The ionized negatively charged
acidic group COO at low pH may be necessary to coordinate a
positive proton H	. Inside the cells, the proton is released in the
neutral pH cytoplasm. CCCP is also a protonophore (37), and
simultaneous application of both compounds leads to an in-
creased bactericidal effect.
The synergy of C6H and valinomycin suggests that the proton
transfer by C6H is partly dependent on themembrane charge, i.e.,
membrane potential itself. C6H transports protons from the out-
side of the cell to the inside, while valinomycin carries potassium
ions from the outside to the inside, seemingly reestablishing the
membrane potential and thus allowing C6H to carry more pro-
tons. It also appears that the rate of proton transport by C6H is
slower than the rate of potassium transport by valinomycin, be-
cause when both are used together the cells are being hyperpolar-
ized, although to a lesser extent than when valinomycin is used on
its own. However, when potassium is present outside the cell, the
synergy between C6H and valinomycin is lost. Salts have inhibi-
tory effects on the bactericidal activity of C6H, whichmight occur
because salts may stabilize themembrane or bind to C6H, altering
its activity.
C6H, unlike CCCP,may not be proton specific and can poten-
tially carry other ions. This provides a potential mechanism to
explain how C6H, after transferring a proton across the mem-
brane, can flip back, carrying another ion, and then transfer a
further proton. IC and liposome data suggest that this secondary
ionwould beK	. CCCP also generates a release of potassium ions,
similarly to nigericin. Cells use the export of potassium ions to
reestablish the membrane potential destroyed by CCCP action
(45, 46). However, the liposome data suggest that C6H can carry
K	 in either direction. Such a nonspecific transport has been pre-
viously described in regard to the effect of various fatty acids on
liposomes (35, 47). This may also explain why, after the initial
depolarization generated byC6H, cells repolarize theirmembrane
within 20 min (Fig. 2). Thus, C6Hmay transport protons and K	
across the cell membrane, with the extent and direction of transfer
being determined by the external and internal environments. Ion
movements generated by C6H flipping across the membrane
might be dependent on a specific protein. Such a mechanism is
present inmitochondria of youngmammals, allowing uncoupling
of the respiratory chain (40, 48, 49). The artificial liposomes used
FIG 6 S. aureusmorphology in the presence of C6H. Transmission electronmicroscopy was used to investigate themorphology of S. aureus after a 2-h standard
killing assay in the presence (B) or absence (A) of 5 g/ml C6H. Scale bars, 0.5 m. The arrows highlight aberrant septation events.
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here suggest that C6H can act independently of protein interac-
tions.
A central question remains as to how C6H actually kills S.
aureus. At concentrations too low to cause overt membrane dis-
ruption, it is not solely the loss of membrane potential (such as
when C6H is used in combination with valinomycin and  re-
mains stable), that leads to increasedmortality. In addition, intra-
cellular ATP levels are better preserved when C6H and valinomy-
cin are used together. The drop in the internal pH level is likely to
affect cell survival, as numerous enzymatic processes are pH de-
pendent within the cells. Another factor that is likely to determine
cell viability is the ability of C6H to induce a clear increase in
membrane fluidity. Thismay lead to uncoupling of the respiratory
chain and disruption of membrane-associated processes leading
to cell division defects, as observed by electron microscopy. Fur-
thermore, studies performed in mitochondria showed that fatty
acidsmodulatemitochondrial reactive oxygen species (ROS) gen-
eration by uncoupling and interfering with electron transport and
also by increasing membrane fluidity (50). Interference of fatty
acids with mitochondrial electron transport is well documented
(51, 52), although itsmolecularmechanism is notwell understood
(50).
Thus, C6H has multiple physiological consequences for S. au-
reus, and previous work has shown dramatic effects on gene ex-
pression (53) and an ability to inhibit virulence factor production
(9). C6H has also been found to be useful in the treatment of both
topical and systemic S. aureus infections (9). This highlights the
potential of C6H as a novel therapy. C6H is included in several
topical human preparations as an emollient (U.S. patent applica-
tion 20110097292) and so does not have serious toxicity issues.
FIG 7 Bactericidal activity of C6H analogues. (A) Various analogues of C6H of the structure shown were chemically synthesized and purified. (B) Antibacterial
activity of C6H (), C8 (Œ), and a fluorescent derivative, Bodipy 1 (). For all data points, the percent survival was compared to that of the wild type at the same
time. All compounds were at 17 M (equivalent to 5 g/ml C8)., Bodipy;, C6H; Œ, C8. (C) Structure of Bodipy 1.
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FIG 8 Subcellular localization of Bodipy 1. S. aureus SH1000was treated with FL-vancomycin and Bodipy 1, washed, and visualized by fluorescencemicroscopy.
(A) DIC; (B) Bodipy 1 labeling; (C) FL-vancomycin labeling; (D) overlay of panels B and C. (E) Line scan through the cell confirming the overall staining of
Bodipy 1 labeling throughout the cell membrane.
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Chemical synthesis of various C6H analogues has not only begun
to identify important features of the molecule, such as the polar
carboxylic acid group, alkenyl/alkynylmoiety, and long hydrocar-
bon chain, but has also highlighted leads for the development of
novel molecules to combat such an important pathogen.
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